BiotechTube
Numab Innovation

Numab Innovation

Zurich, Switzerland· Est.
numab.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $122M

Overview

Numab Therapeutics is a Zurich-based biotech pioneering a rational, platform-based approach to design multispecific antibodies with tailored pharmacokinetics. The company's core value proposition lies in its proprietary λ-Cap™ and MATCH™ technologies, which enable the reproducible creation of novel therapeutics intended to overcome limitations of first-generation antibodies. It is advancing a proprietary pipeline led by NM26 for atopic dermatitis while simultaneously validating its platform through multiple high-value collaborations with partners like Boehringer Ingelheim and Kaken Pharmaceutical. The recent appointment of a seasoned CEO with significant commercial and deal-making experience signals a maturation phase focused on pipeline advancement and strategic partnerships.

ImmunologyOncologyOphthalmology

Technology Platform

Proprietary λ-Cap™ and MATCH™ platforms for the rational, modular, and reproducible design and assembly of multispecific antibody-based therapeutics with tailored pharmacokinetic properties.

Funding History

2
Total raised:$122M
Series B$100M
Series A$22M

Opportunities

The large and growing markets for advanced biologics in immunology (e.g., atopic dermatitis, IBD) and oncology present a significant opportunity for Numab's multispecific antibodies, which aim for superior efficacy.
The company's platform approach allows for rapid expansion into new disease areas, as evidenced by its partnerships in ophthalmology, creating multiple shots on goal.
Strategic partnerships provide non-dilutive funding, de-risk development, and validate the technology for potential future M&A interest.

Risk Factors

The lead candidate NM26 faces inherent clinical trial risks, where failure in efficacy or safety would be a major setback.
The competitive landscape for multispecific antibody platforms is intense, with risk of technological obsolescence.
Dependency on partners for key programs introduces execution risk if partners change strategic priorities or fail to develop assets effectively.

Competitive Landscape

Numab operates in the highly competitive multispecific antibody space, competing with large-cap biotechs like Genmab (DuoBody), Regeneron, and Roche, as well as numerous platform-focused biotechs such as AbCellera, Zymeworks, and Teneobio. Differentiation hinges on the simplicity, reproducibility, and drug-like properties of molecules produced by its λ-Cap™/MATCH™ system. Its early partnerships with top-tier pharma provide a competitive validation edge.

More companies in Biologics / Biosimilars →More companies in Switzerland →